Trial Profile

A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WZTL-002 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Acronyms ENABLE; ENABLE-1

Most Recent Events

12 Jun 2024 Planned End Date changed from 1 Feb 2029 to 1 Mar 2029.
12 Jun 2024 Status changed from recruiting to active, no longer recruiting.
12 Dec 2023 According to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, enrolment to a dose expansion cohort has commenced and will assess outpatient management and the safety and efficacy of WZTL-002 CAR T-cells.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com